

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/074,754

WHICH CLAIMS PRIORITY TO PROVISIONAL APPLICATION NO.

60/268,357, FILED FEBRUARY 13, 2001

Applicant

MARKS, et al.

Filed

: February 13, 2002

Title

METHODS AND REAGENTS FOR DISCOVERING AND USING

MAMMALIAN MELANOCORTIN RECEPTOR ANTAGONISTS TO TREAT

CACHEXIA

Art Unit

1646

Examiner

CHANDRA, GYAN

Atty Docket No.

OHSU-0015-CN1

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.51(d), 1.56, 1.97 and 1.98, this Information Disclosure Statement is submitted in the above-identified patent application. A listing of documents to be published on the face of any patent granted from this application is submitted herewith on Form PTO/SB/08. Any other documents or information submitted for consideration by the Examiner are listed in this paper. A copy of each foreign patent, or each publication or portion thereof listed or herein identified, is submitted herewith, except that a copy of any U.S. patent application identified herein or any patent, publication or other information listed herein cited or submitted in a prior application relied upon for an earlier filing date under 35 U.S.C. § 120 and identified below, is not submitted herewith.

CERTIFICATION

This Information Disclosure Statement is submitted after the earlier of the mailing date of a final rejection or Notice of Allowance sent in this application but before payment of the Issue Fee. The certification required under 37 C.F.R. § 1.97(e) is submitted below.

12/06/2006 MBERHE

00000118 10074754

* * *

02 FC:180%

189.93 OP

The Commissioner is hereby authorized to charge payment of any fees associated with this communication, including fees under 37 C.F.R. §§ 1.16 and 1.17 or credit any overpayment to **Deposit Account Number 10-0233-OHSU-0015-CN1.**

The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.

Respectfully submitted,

Denise L. Mayfield Registration Number 33,732

Customer Number 22,506

JAGTIANI + GUTTAG Democracy Square Business Center 10363-A Democracy Lane Fairfax, Virginia 22030 (703) 591-2664

December 5, 2006

PTO/SB/08b (08-03)

DEC 0'5 2006 Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

nder	the	Papen	<u>work</u>	Reduc	<u>ction</u>	Act of	1995
	C	hetituto	for E	arm DT	· 0 1	140	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of Sheet

Complete If Known				
Applicant Number	10/074,754			
Filing Date	February 13, 2002			
First Named Inventor	MARKS, et al.			
Art Unit	1646			
Examiner Name	CHANDRA, Gyan			
Attorney Docket Number	OHSU-0015-CN1			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. MARKS, et al. "Role of the Central Melanocortin System in Cachexia" Cancer Research, 61 (Feb. 2001), PGS. 1432-1438	T ²		
		MARKS, et al. "Role of the Central Melanocortin System in Cachexia" Cancer Research, 61 (Feb. 2001), PGS. 1432-1438			
			 -		
	ļ				
	ļ				
ļ	 		ļ		
			ļ,		
			ļ		
			·		

Examiner's	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.